Articles

Mechanisms of acquired resistance to anti–PD-(L)1 therapy in patients with advanced NSCLC are heterogeneous and require novel therapeutic strategies to be surmounted. Read More ›

Administering nivolumab in the morning improved progression-free survival and overall survival compared with administration during later times of the day, suggesting that circadian rhythm may affect its efficacy. Read More ›

Patients with NSCLC with poor performance status (PS) had significantly worse survival outcomes and were more likely to utilize healthcare services than those with favorable PS. Read More ›

Transcriptional signatures of COPII vesicle and Golgi targeting were identified as potential novel response biomarkers to vidutolimod, a first-in-class CpG-A TLR9 agonist, in combination anti–PD-L1-targeted therapy. Read More ›

The 5-year extended follow-up of CheckMate 227 demonstrated that nivolumab plus ipilimumab continued to provide durable clinical benefit in previously untreated patients with metastatic NSCLC compared with chemotherapy regardless of PD-L1 expression level. Read More ›

Mutations in the ATM gene, the most mutated DNA damage and repair gene in cancer, were found to define distinct subsets of patients with NSCLC with unique genomic characteristics, clinicopathologic features, and sensitivity to chemoimmunotherapy. Read More ›

A noncoding single-nucleotide polymorphism in the CTLA-4 gene was found to be common among responders to anti–PD-1/PD-L1 therapies, which may enhance the clinical effect of PD-1 blockade. Read More ›

In real-world practice, the combination of immune checkpoint inhibitors with chemotherapy in patients with metastatic NSCLC may delay progression compared with immune checkpoint inhibitors alone but does not affect long-term outcomes. Read More ›

Combining anti–PD-(L)-1 with chemotherapy for the treatment of patients with a high PD-L1 expression level did not improve survival compared with anti–PD-(L)-1 monotherapy. Read More ›

Treatment of patients with advanced PD-L1–high NSCLC with a combination of immune checkpoint inhibitors and chemotherapy resulted in comparable or better outcomes than immune checkpoint inhibitors alone; however, tolerability was a limiting factor for elderly patients. Read More ›